PBMs Want To Distribute New Rebate Payments; Pharmacists Disagree
Published by Inside Health Policy
The Trump administration’s point-of-sale rebate proposal would drastically alter the way rebates are delivered, and pharmacy benefit managers are angling for responsibility to distribute the rebates under the new model. PBMs have signaled they could sue the administration if they don’t like the way the final rebate rule is structured. Pharmacists, on the other hand, want an entity other than PBMs to fill the intermediary role between manufacturers and pharmacies.
Currently, PBMs pay pharmacies for drugs, then they get rebates from drug makers that are passed to plans, though PBMs often keep some of the rebates. Under the new rebate proposal, drug makers would pay the rebates, directly or indirectly, straight to the pharmacies.
The HHS Office of Inspector General uses the term “chargeback” to describe these new payments, even though the word is already an established term of art for payments between manufacturers and wholesalers, said CiiTA Managing Director Jason Hardaway.
In comments to the administration, the PBM lobby made clear that it was strongly opposed to the point-of-sale rebate proposal and argued the government does not have authority to make the regulatory changes. However, if the proposal were implemented, the group wants changes that would let PBMs act as intermediaries to distribute the rebate payments to pharmacies.
The Pharmaceutical Care Management Association said PBMs are best suited to continue acting as middlemen if the new system is implemented. Funneling rebates to the point of sale would require a new payment system, and pharmacists would need more data than they currently use to calculate patient costs, the PBM lobby said. PCMA argued that PBMs already have the infrastructure to work with major health care systems, plans and pharmacies; they have the information necessary to inform point-of-sale price calculations for beneficiaries; and building a new model from scratch would be costly and time-consuming.
Click here to see the original article on the Inside Health Policy website.
Recent Posts
-
LTC pharmacies said this would happen. New data says they were right.
By Donna Shryer // Published July 18, 2026 in McKnight’s Long-Term Care News Long-term care pharmacies predicted a steep reimbursement hit from the Inflation Reduction Act’s Medicare drug pricing changes. Now they say they have the data confirming it. A new analysis of member financial data shows reimbursement for drugs subject to the law’s negotiated […]
-
New Analysis Confirms Drug Pricing Changes Hurt LTC Pharmacies, Reinforces Need for Sustainable Payment Reform
Washington, D.C. (July 16, 2026)— A new analysis of member provided financial data confirms what the Senior Care Pharmacy Coalition (SCPC) has warned: the Inflation Reduction Act’s (IRA) Medicare drug pricing provisions that went into effect in 2026 have significantly reduced reimbursement for long-term care (LTC) pharmacies, threatening their financial sustainability and the benefits of […]
-
LTC Pharmacies Double Down On Call For PBM Contract Negotiation Reform
Lauren Brensel // Inside Health Policy – July 23, 2026 A group representing long-term care pharmacies is reminding policymakers of the negative impacts that result from problematic contract negotiations with pharmacy benefit managers, asking CMS to help alleviate pharmacies’ disputes with the three largest PBMs by embracing a series of reforms. LTC pharmacy services like […]
Stay Connected
Get the latest news and updates on issues impacting the long-term care pharmacy community.